FDA staff cited "substantial toxicity" risks associated with vandetanib, AstraZeneca's experimental drug for medullary thyroid cancer. About 31% of patients who received the treatment in a study experienced adverse effects, compared with 13% of those given placebo, the reviewers said. The agency's report was issued ahead of a panel review of the medicine Thursday.

Full Story:

Related Summaries